Refine Search
(36)
(206)
(599)
(1469)

The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area

  • $275
  • February 2018
Add to Basket Quick View Add to Saved List

For the biopharmaceutical industry, 2017 was marked by noteworthy innovation as well as disappointments across therapy areas, set against a backdrop of remarkable advances in technology in healthcare and the growing presence of biosimilars. Eac...

PharmSource - Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015

  • $295
  • February 2014
Add to Basket Quick View Add to Saved List

The pharmaceutical R&D services market is sending conflicting signals: new clinical trial starts are down, IPOs are up and start-ups are having trouble raising funding. With such contradictory information, how can R&D service providers ...

FDA Approves Erivedge (Vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma

  • $500
  • February 2012
Add to Basket Quick View Add to Saved List

GlobalData, the industry analysis specialist, has released its new view point, “FDA Approves Erivedge (vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma”. The report is an essential source of information on the approval of Eri...

Impact of Eurozone Crisis on Healthcare Economics

  • $500
  • February 2012
Add to Basket Quick View Add to Saved List

GlobalData, the industry analysis specialist, has released its new view point, “Impact of Eurozone Crisis on Healthcare Economics”. The report is an essential source of information for the analysis on the impact of the Eurozone crisis on the he...

Xgeva’s Safety and Efficacy Failings Put Future of Amgen Drug in Question

  • $500
  • February 2012
Add to Basket Quick View Add to Saved List

GlobalData, the industry analysis specialist, has released its new viewpoint, “Xgeva’s Safety and Efficacy Failings Put Future of Amgen Drug in Question”. The report is an essential source of information for the analysis of scope of approval fo...

Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation

  • $500
  • February 2012
Add to Basket Quick View Add to Saved List

The viewpoint is an essential source of information and analysis on the KALYDECO (ivacaftor, VX-770) for the treatment of Cystic Fibrosis (CF) patients with G551D mutation. The viewpoint provides insights on the product clinical information and...

Which Strategies can Big Pharmaceutical Companies Use to Manage the Impact of Patent Protection Loss?

  • $500
  • January 2012
Add to Basket Quick View Add to Saved List

The viewpoint is an essential source of information and analysis on the patent protection strategies by Big Pharma along with the case studies. The viewpoint provides insights on the companies as well as products that were launched to minimise ...

Tensions Rising between Branded Drugmakers and Health Plans

  • $500
  • March 2012
Add to Basket Quick View Add to Saved List

GlobalData's new alert "Tensions Rising between Branded Drugmakers and Health Plans" analyzes the Co-Pay Coupon lawsuit and the implications for branded drugmakers and health plan providers. Large pharmaceutical companies are in t...

Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders

  • $500
  • April 2012
Add to Basket Quick View Add to Saved List

GlobalData’s new alert, “Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders” takes a look at gene therapy for the treatment of blood disorders such as beta-thalassemia and sickle cell anemia. An international team o...

A Tale of Two Multiple Myeloma Therapies - The Race for Accelerated Approval

  • $500
  • May 2012
Add to Basket Quick View Add to Saved List

Multiple myeloma patients with relapsed and refractory disease are underserved by current pharmaceutical offerings. Two drugs, Onyx’s proteasome inhibitor carfilzomib and Celgene’s immunomodulatory drug pomalidomide, are currently being evalua...

Afinitor - A Two-Pronged Attack Against Tuberous Sclerosis Complex

  • $500
  • May 2012
Add to Basket Quick View Add to Saved List

GlobalData’s new alert, Afinitor: A Two-Pronged Attack Against Tuberous Sclerosis Complex,” takes a look at the implications of the FDA’s recent approval of the drug for the treatment of angiomyolipomas, benign kidney tumors that affect a major...

The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area

  • $500
  • March 2018
Add to Basket Quick View Add to Saved List

2018 promises to be a year of continued innovation in the biopharmaceutical industry across therapy areas. In this report, GlobalData’s analysts highlight a selection of highly anticipated events, including regulatory approvals, product launche...

Brexit and the Healthcare Industry – Implications for Pharma, Q3 2018

  • $500
  • November 2018
Add to Basket Quick View Add to Saved List

It has been over two years since the UK voted to leave the EU. As Brexit deadlines loom, negotiations are still ongoing to determine the UK’s relationship with the EU after Brexit.

This report provides an assessment of how the pharmaceuti...

Brexit and the Healthcare Industry – Implications for Pharma, Q1 2018

  • $500
  • May 2018
Add to Basket Quick View Add to Saved List

It has been almost two years since the UK voted to leave the EU. Businesses were told a vote to leave the EU would drive the UK into a severe recession, yet markets are up. Negotiations are ongoing to determine the UK’s post-Brexit relationship...

General Data Protection Regulation (GDPR) in the Healthcare Industry – Implications for Healthcare – H1 2018

  • $500
  • July 2018
Add to Basket Quick View Add to Saved List

The EU voted to implement updated data protection laws in the form of the General Data Protection Regulation (GDPR) in April 2016. GDPR came into force on May 25, 2018, providing EU citizens with greater rights and control regarding the process...

Brexit and the Healthcare Industry – Implications for Pharma, Q2 2018

  • $500
  • August 2018
Add to Basket Quick View Add to Saved List

It has been over two years since the UK voted to leave the EU. Businesses were told a vote to leave the EU would drive the UK into a severe recession, yet markets are up. Negotiations are ongoing to determine the UK’s relationship with the EU a...

Brexit and the Healthcare Industry Implications for Pharma – the Story so Far

  • $500
  • March 2019
Add to Basket Quick View Add to Saved List

It may take up to five years for the healthcare industry to stabilize in the event of a ‘no deal’ Brexit. This is the consensus opinion among professionals surveyed in the pharmaceutical industry, according to GlobalData, a leading data and ana...

Brexit and the Healthcare Industry – Implications for Pharma – Q2 2019

  • $500
  • July 2019
Add to Basket Quick View Add to Saved List

It has been over three years since the UK voted to leave the EU. After the UK and the EU agreed to a second delay to Brexit, it is due to happen on 31 October, 2019 and negotiations are still ongoing to determine the UK’s relationship with the ...

PharmSource - CMO Market Penetration as Evidenced by Outsourced NDA Approvals, 2014 Edition

  • $600
  • April 2014
Add to Basket Quick View Add to Saved List

Geared to bio/pharma contract manufacturers, as well as to bio/pharmaceutical company procurement executives making sourcing decisions, this proprietary 82012 NDA briefing-page analysis reveals that CMOs failed to gain share of outsourced NDA a...

PharmSource - 2012 NDA Review: CMOs Tread Water

  • $600
  • April 2013
Add to Basket Quick View Add to Saved List

Geared to bio/pharma contract manufacturers, as well as to bio/pharmaceutical company procurement executives making sourcing decisions, this proprietary 10-page analysis gives critical insight into evolving contract manufacturing trends and dev...

PharmSource - Opportunity Knocks: In-Licensed Drug Products Can Signal Outsourcing Opportunity

  • $750
  • November 2014
Add to Basket Quick View Add to Saved List

Of the more than 230 New Molecular Entities (NMEs) approved between 2003-2013, over one-third were in-licensed by the sponsor receiving the approval. A significant difference in manufacturing status emerged between products originally discovere...

PharmSource - Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing

  • $750
  • October 2014
Add to Basket Quick View Add to Saved List

Investment in captive manufacturing capacity by bio/pharma companies is an indicator of the industry’s intentions with respect to outsourcing. Based on recent capital expenditure trends, it’s clear that bio/pharma companies would rather “make t...

PharmSource - CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead

  • $925
  • November 2014
Add to Basket Quick View Add to Saved List

Emerging bio/pharmaceutical companies are benefiting from a surge in financing from venture capital, IPOs and secondary offerings. Funding raised in the first half of 2014 is double what was raised in the same period of 2013. R&D spending b...

The Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to Burst

  • $995
  • June 2012
Add to Basket Quick View Add to Saved List

GlobalData's analysis alert "The Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to Burst”,analyzes the current pipeline for rheumatoid arthritis drug therapeutics. In addition to the antici...

Congress on Track to Overcome Partisan Gridlock and Keep the FDA Afloat

  • $995
  • May 2012
Add to Basket Quick View Add to Saved List

GlobalData's analysis alert "Congress On Track to Overcome Partisan Gridlock and Keep the FDA Afloat " analyzes legislation recently passed by the United States Senate updating the Prescription Drug User Fee Act (PDUFA) and rela...

PharmSource - Bio/Pharma CapEx Trends 2016

  • $997
  • September 2016
Add to Basket Quick View Add to Saved List

Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. Based on recent capital expenditure trends, it’s clear that bio/pharma companies would rather “make than buy.”

Accord...

PharmSource - Not So NICE: How Market Access Schemes Impact the CMO Sector

  • $997
  • June 2014
Add to Basket Quick View Add to Saved List

This 15-page expert analysis explains why economic austerity forces Europe’s state-funded health-care systems to limit patient access to just those pharmaceuticals with clearly proven health and cost benefits. Contract manufacturing organizatio...

Partnerships, Licensing, Investments and M&A Deals and Trends for November 2016 in Pharmaceuticals

  • $1,000
  • January 2017
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for November 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) a...

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals

  • $1,000
  • March 2017
Add to Basket Quick View Add to Saved List

The pharmaceutical and healthcare industry reported a decrease in the number of deals and an increase in deal values in January 2017. The industry reported 332 deals worth USD54.9 billion in January 2017, compared to 344 deals worth USD29.1 bi...

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceuticals

  • $1,000
  • February 2017
Add to Basket Quick View Add to Saved List

The pharmaceutical and healthcare industry reported an increase in the number of deals and a decrease in deal values in December 2016. The industry reported 324 deals worth USD27.9 billion in December 2016, compared to 313 deals worth USD33.9 b...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2011

  • $1,000
  • February 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals February 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and f...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - May 2011

  • $1,000
  • May 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals May 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financ...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - June 2011

  • $1,000
  • June 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals June 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and finan...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - July 2011

  • $1,000
  • July 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals July 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and finan...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - August 2011

  • $1,000
  • July 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals August 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and fin...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - September 2011

  • $1,000
  • September 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals September 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and ...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011

  • $1,000
  • October 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals October 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and fi...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - November 2011

  • $1,000
  • October 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals Novemeber 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and ...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011

  • $1,000
  • December 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals December 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and f...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - January 2012

  • $1,000
  • January 2012
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals January 2012” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and fi...

BioDelivery Sciences International Prices Private Placement of $15m

  • $1,000
  • March 2011
Add to Basket Quick View Add to Saved List

GlobalData’s report, “BioDelivery Sciences International Prices Private Placement of $15m” provides key information on future plans of BioDelivery Sciences International. This report wil provide a background of the products being developed by t...

Cephalon To Acquire Gemin X Pharmaceuticals

  • $1,000
  • April 2011
Add to Basket Quick View Add to Saved List

GlobalData’s report, “Cephalon To Acquire Gemin X Pharmaceuticals” provides key information on the acquisition and long terms plans of Cephalon. This report will help you to assess the dynamics of the deal and its rationale. It will provide you...

63rd Annual Meeting of the American Academy of Neurology - Post Conference Review and Analysis

  • $1,000
  • May 2011
Add to Basket Quick View Add to Saved List

GlobalData, the industry analysis specialist, has released its new conference alerts, “63rd Annual Meeting of the American Academy of Neurology: Review and Analysis”. The conference alert is an essential source of information and analysis on th...

Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012

  • $1,000
  • April 2012
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012" provides data on the Viral Respiratory Tract Infection clinical trial scenario. This report provides elemental information ...

Traumatic Brain Injury Global Clinical Trials Review, H1, 2012

  • $1,000
  • April 2012
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Traumatic Brain Injury Global Clinical Trials Review, H1, 2012" provides data on the Traumatic Brain Injury clinical trial scenario. This report provides elemental information and data relating to t...

Obstructive Pulmonary Disease Global Clinical Trials Review, H1, 2012

  • $1,000
  • April 2012
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Obstructive Pulmonary Disease Global Clinical Trials Review, H1, 2012" provides data on the Obstructive Pulmonary Disease clinical trial scenario. This report provides elemental information and data...

Diabetic Retinopathy Global Clinical Trials Review, H1, 2012

  • $1,000
  • April 2012
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Diabetic Retinopathy Global Clinical Trials Review, H1, 2012" provides data on the Diabetic Retinopathy clinical trial scenario. This report provides elemental information and data relating to the c...

Cluster Headache Syndrome Global Clinical Trials Review, H1, 2012

  • $1,000
  • April 2012
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Cluster Headache Global Clinical Trials Review, H1, 2012" provides data on the Cluster Headache clinical trial scenario. This report provides elemental information and data relating to the clinical ...

PharmSource - Catching a Wave: How Much Will CMOs Benefit From Biosimilars?

  • $1,000
  • January 2015
Add to Basket Quick View Add to Saved List

Regulatory developments in the United States, coupled with impending patent expiry, have paved the way for the introduction of biosimilars of increasing technical complexity. In the European Union, 20 first wave biosimilars, consisting of growt...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – January 2011

  • $1,000
  • January 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals January 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and fi...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – March 2011

  • $1,000
  • March 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals March 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and fina...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - April 2011

  • $1,000
  • March 2011
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals April 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and fina...

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2013 in Pharmaceuticals

  • $1,000
  • January 2014
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for December 2013 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) a...

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2014 in Pharmaceuticals

  • $1,000
  • March 2014
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for January 2014 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) an...

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2014 in Pharmaceuticals

  • $1,000
  • March 2014
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2014 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) a...

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2014 in Pharmaceuticals

  • $1,000
  • January 2015
Add to Basket Quick View Add to Saved List

"GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for December 2014 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&...

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2015 in Pharmaceuticals

  • $1,000
  • March 2015
Add to Basket Quick View Add to Saved List

"GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for January 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&...

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2015 in Pharmaceuticals

  • $1,000
  • March 2015
Add to Basket Quick View Add to Saved List

"GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&...

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals

  • $1,000
  • May 2015
Add to Basket Quick View Add to Saved List

"GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As...

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2015 in Pharmaceuticals

  • $1,000
  • May 2015
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for April 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and ...

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2015 in Pharmaceuticals

  • $1,000
  • June 2015
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for May 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and fi...

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2015 in Pharmaceuticals

  • $1,000
  • August 2015
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for June 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and f...

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2015 in Pharmaceuticals

  • $1,000
  • September 2015
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and f...

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2015 in Pharmaceuticals

  • $1,000
  • October 2015
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for August 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and...

Partnerships, Licensing, Investments and M&A Deals and Trends for September 2015 in Pharmaceuticals

  • $1,000
  • November 2015
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for September 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) ...

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2015 in Pharmaceuticals

  • $1,000
  • December 2015
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for October 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) an...

Partnerships, Licensing, Investments and M&A Deals and Trends for November 2015 in Pharmaceuticals

  • $1,000
  • December 2015
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for November 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) a...

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2015 in Pharmaceuticals

  • $1,000
  • February 2016
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for December 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) a...

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals

  • $1,000
  • March 2016
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) an...

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2016 in Pharmaceuticals

  • $1,000
  • April 2016
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) a...

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2016 in Pharmaceuticals

  • $1,000
  • May 2016
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for March 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and ...

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2016 in Pharmaceuticals

  • $1,000
  • June 2016
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for April 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and ...

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2016 in Pharmaceuticals

  • $1,000
  • July 2016
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for May 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and fi...

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2016 in Pharmaceuticals

  • $1,000
  • August 2016
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for June 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and f...

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2016 in Pharmaceuticals

  • $1,000
  • September 2016
Add to Basket Quick View Add to Saved List

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and f...

Join our mailing list
Find out first about the latest reports and offers.
Report Catalogue

Strategic Insight Reports

Market Analysis Reports

Databooks